June 28, 2018 08:50 AM EDT

Sarcoma expert George Demetri grades the latest statement on Nanobiotix's late-stage drug NBTXR3

John Carroll

Editor & Founder

The first glance at Nanobiotix’s recent round of data for its drug NBTXR3 revealed positive, but not powerful, data when used against soft tissue sarcoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sarcoma expert George Demetri grades the latest statement on Nanobiotix's late-stage drug NBTXR3

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FDA is poised to pull Ocaliva as adcomm documents question post-approval study results

FDA criticizes AbbVie's 'misleading' ad with Serena Williams

Roche says its Carmot-acquired obesity pill is effective in early study

House passes Biosecure Act, sending Chinese biotech ban to Senate

CVS says it won't correct congressional testimony

Novo Nordisk's longstanding GLP-1 reduced BMI by 7% in children in Phase 3 trial

Sar­co­ma ex­pert George Demetri grades the lat­est state­ment on Nanobi­otix's late-stage drug NBTXR3

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Sarcoma expert George Demetri grades the latest statement on Nanobiotix's late-stage drug NBTXR3